That sounds right Josimar. Thank you. Something along the lines of asx listings, with the inference drawn that perhaps exergen had ideas of taking over mnm as a vehicle for that purpose.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
